These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32428800)

  • 1. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
    Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
    Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
    Isaka T; Ito H; Nakayama H; Yokose T; Saito H; Adachi H; Miura J; Shigefuku S; Kikuchi A; Rino Y
    Lung Cancer; 2021 Dec; 162():128-134. PubMed ID: 34775216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
    Yang H; Wang K; Li S; Li Y; Yuan L
    Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
    [No Abstract]   [Full Text] [Related]  

  • 4. Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
    Chou HP; Lin KH; Huang HK; Lin LF; Chen YY; Wu TH; Lee SC; Chang H; Huang TW
    Eur Radiol; 2021 Oct; 31(10):8021-8029. PubMed ID: 33763721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
    Stanic K; Turnsek N; Vrankar M
    Radiol Oncol; 2019 Nov; 53(4):453-458. PubMed ID: 31747381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic significance of blood and lymphatic vessel invasion in pathological stage IA lung adenocarcinoma in the 8th edition of the TNM classification.
    Samejima J; Yokose T; Ito H; Nakayama H; Nagashima T; Suzuki M; Hamanaka R; Yamada K; Masuda M
    Lung Cancer; 2019 Nov; 137():144-148. PubMed ID: 31593845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
    Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
    Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
    Noma D; Inamura K; Matsuura Y; Hirata Y; Nakajima T; Yamazaki H; Hirai Y; Ichinose J; Nakao M; Ninomiya H; Mun M; Nakagawa K; Masuda M; Ishikawa Y; Okumura S
    Clin Lung Cancer; 2018 Jan; 19(1):e109-e122. PubMed ID: 29066222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
    BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
    Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
    Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
    Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
    Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
    Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.
    Zhai W; Duan F; Li D; Yan Q; Dai S; Zhang B; Wang J
    Eur J Surg Oncol; 2022 Apr; 48(4):752-760. PubMed ID: 34620508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
    Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
    Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
    Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
    Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
    Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
    Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
    Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.